Clinical Trial Update: A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating Rocbrutinib in participants with relapsed or refractory Non-GCB diffuse large B-cell lymphoma and is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Rocbrutinib (rocbrutinib)

Snippet

Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. | Conditions: Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Status: RECRUITING